Protagonist Therapeutics Inc (PTGX)
NASDAQ:PTGX
Want to see PTGX full AI Analyst Report?
Total Valuation
Protagonist Therapeutics has a market cap or net worth of $6.49B. The enterprise value is $6.38B.
Market Cap$6.49B
Enterprise Value$6.38B
Share Statistics
Protagonist Therapeutics has 64,311,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,311,370
Owned by Insiders1.19%
Owned by Institutions42.82%
Financial Efficiency
Protagonist Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.23%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-25.23%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee371.10K
Profits Per Employee0.00
Employee Count124
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagonist Therapeutics is 453.4. Protagonist Therapeutics’s PEG ratio is 0.29.
PE Ratio453.4
PS Ratio120.66
PB Ratio9.03
Price to Fair Value9.03
Price to FCF99.01
Price to Operating Cash Flow-56.93
PEG Ratio0.29
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of 46.02M and earned -130.15M in profits. Earnings per share was -2.05.
Revenue46.02M
Gross Profit44.79M
Operating Income-158.13M
Pretax Income-129.31M
Net Income-130.15M
EBITDA-128.09M
Earnings Per Share (EPS)-2.05
Cash Flow
In the last 12 months, operating cash flow was -116.64M and capital expenditures 330.00K, giving a free cash flow of -116.31M billion.
Operating Cash Flow-116.64M
Free Cash Flow-116.31M
Free Cash Flow per Share-1.81
Dividends & Yields
Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change123.41%
50-Day Moving Average101.17
200-Day Moving Average83.02
Relative Strength Index (RSI)51.54
Average Volume (3m)638.34K
Important Dates
Protagonist Therapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Protagonist Therapeutics as a current ratio of 12.71, with Debt / Equity ratio of 1.49%
Current Ratio12.71
Quick Ratio12.71
Debt to Market Cap<0.01
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagonist Therapeutics has paid 838.00K in taxes.
Income Tax838.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Protagonist Therapeutics EV to EBITDA ratio is -42.43, with an EV/FCF ratio of 96.90.
EV to Sales118.10
EV to EBITDA-42.43
EV to Free Cash Flow96.90
EV to Operating Cash Flow94.23
Balance Sheet
Protagonist Therapeutics has $547.79M in cash and marketable securities with $9.78M in debt, giving a net cash position of $538.01M billion.
Cash & Marketable Securities$547.79M
Total Debt$9.78M
Net Cash$538.01M
Net Cash Per Share$8.37
Tangible Book Value Per Share$9.67
Margins
Gross margin is 99.45%, with operating margin of -343.63%, and net profit margin of -282.83%.
Gross Margin99.45%
Operating Margin-343.63%
Pretax Margin-281.01%
Net Profit Margin-282.83%
EBITDA Margin-278.35%
EBIT Margin-281.01%
Analyst Forecast
The average price target for Protagonist Therapeutics is $117.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$117.00
Price Target Upside10.40% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast-64.36%
EPS Growth Forecast-302.09%